ArticleTrials2024

Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial.

David W J Griffin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.